Hiroshi Miyamoto, MD, PhD, completed his medical school and urology residency training followed by clinical urology practice and translational research in genitourinary cancers in Japan. In 1996, he moved to the United States to conduct postdoctoral research at University of Wisconsin - Madison and University of Rochester. He then completed anatomic pathology residency training at University of Rochester Medical Center and clinical fellowship in urologic pathology at The Johns Hopkins Hospital. Since 2009, he has been the faculty as a surgical pathologist as well as an independent investigator at University of Rochester School of Medicine and Dentistry (2009-2013 & 2016-present) and Johns Hopkins University School of Medicine (2013-2016). He is currently the Director of Genitourinary Pathology at University of Rochester Medical Center.
Dr. Miyamoto’s primary research interest includes molecular biology of steroid hormone receptors in genitourinary tumors. Specifically, he has been investigating the role of androgen receptor signals in the development and progression of urothelial cancer. Epidemiological and clinical data indicate that men have a substantially higher risk of bladder cancer, whereas women tend to present with more aggressive tumors. The underlying mechanisms of how androgens regulate urothelial tumorigenesis and tumor outgrowth will offer explanations for these gender-specific differences in cancer incidence and aggressiveness. He has also assessed the effects of new classes of androgen receptor antagonists on prostate cancer progression and has characterized novel androgen receptor co-regulators in prostate cancer cells. He has published more than 160 peer-reviewed articles and 17 book chapters.